Melphalan exposure and outcome in obese and non-obese adults with myeloma. A study of pharmacokinetics and pharmacodynamics

[1]  M. Norkin,et al.  Effect of Conditioning Regimen Dose Reduction in Obese Patients Undergoing Autologous Hematopoietic Cell Transplantation. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[2]  I. Kerridge,et al.  High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantation. , 2016, British journal of clinical pharmacology.

[3]  M. Perales,et al.  Conditioning chemotherapy dose adjustment in obese patients: a review and position statement by the American Society for Blood and Marrow Transplantation practice guideline committee. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[4]  G. Rosner,et al.  Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  B. Barlogie,et al.  Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  I. Kerridge,et al.  Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy. , 2010, British journal of clinical pharmacology.

[7]  D. DuBois,et al.  A formula to estimate the approximate surface area if height and weight be known , 1989 .

[8]  M. McCarron,et al.  Clinical Pharmacy: Case Studies , 1974 .

[9]  D. D. Bois,et al.  CLINICAL CALORIMETRY: TENTH PAPER A FORMULA TO ESTIMATE THE APPROXIMATE SURFACE AREA IF HEIGHT AND WEIGHT BE KNOWN , 1916 .

[10]  J. Thigpen.  Appropriate Chemotherapy Dosing for Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline , 2012 .

[11]  Stephen B. Duffull,et al.  Quantification of Lean Bodyweight , 2005, Clinical pharmacokinetics.

[12]  W. A. Edwards,et al.  Influence of weight on aminoglycoside pharmacokinetics in normal weight and morbidly obese patients , 2004, European Journal of Clinical Pharmacology.

[13]  Cockcroft Dw,et al.  Prediction of Creatinine Clearance from Serum Creatinine , 1976 .

[14]  Sarayut Janmahasatian.  Quantification of lean body weight , 2022 .